Rofecoxib

@article{Hillson2000Rofecoxib,
  title={Rofecoxib},
  author={J. Hillson and D. Furst},
  journal={Expert Opinion on Pharmacotherapy},
  year={2000},
  volume={1},
  pages={1053 - 1066}
}
  • J. Hillson, D. Furst
  • Published 2000
  • Expert Opinion on Pharmacotherapy
    • Rofecoxib (Vioxx™, Merck & Co., Inc.) is a new orally-effective non-steroidal anti-inflammatory drug (NSAID) approved for treatment of acute pain, fever, primary dysmenorrhea and pain and inflammation in osteoarthritis (OA). It is also being evaluated for treatment of rheumatoid arthritis and adenomatous polyps of the colon. Rofecoxib is a specific inhibitor of cyclooxygenase-2 (COX-2), thereby inhibiting prostanoid synthesis in cells that express COX-2, including inflammatory cells. As cells… CONTINUE READING
    View on Taylor & Francis

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 68 REFERENCES
    Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
    • 690
    • Open Access
    Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.
    • 1,390
    • Open Access
    Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial.
    • 249
    Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial.
    • 230
    Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis.
    • 1,212
    Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial.
    • 133
    Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo
    • 418
    • Open Access
    Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis
    • 812
    • Open Access
    The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group.
    • 136
    Cyclooxygenase‐2 inhibition by rofecoxib reverses naturally occurring fever in humans
    • 90